Natural product-derived therapy for tuberculosis: Ganoderma lucidum, a medicinal/herbal mushroom, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 29/November/2016, 8.39 pm

Natural product-derived anti-ageing therapy: 2,4,5-trihydroxybenzaldehyde (TDB), found in Geum japonicum and Polygonum cuspidatum (PC), also known as Japanese knotweed, increases NMN levels, decreases age-associated weight gain, augments energy metabolism, improves physical activity and insulin sensitivity, promotes healthy lipid profile, and improves eye function via down regulation of its target gene, 29/November/2015, 10.10 am
November 29, 2016
MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-3646 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 29/November/2016, 10.04 pm
November 29, 2016
Show all

IntroductionWhat they say

A study from the Max Plank Institute for Infection Biology, Berlin, Germany shows that “CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis.” This study was published in the 10 February 2014 issue of the“Journal of Clinical Investigation” [One of the best research journals in clinical medicine with an impact factor of 12.575] by Prof. Stefan H.E. Kaufman MJ, Geraldine Nouailles, and others.


What we say: 

price-300

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for tuberculosis: Ganoderma lucidum, a medicinal/herbal mushroomincreases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene


What is known? 

Prof. Stefan Kaufman’s research team has shown earlier that knockdown of CXCL5 in mice inhibits recruitment of polymorphonuclear leukocytes, decreases pulmonary inflammation and inhibits the progression of pulmonary tuberculosis.


From Significance of the study to Public health relevance:

Given that: (1) nearly 2.5 billion people out of 7.4 billion total world population are infected with M. tuberculosis; (2) majority of population in Asian and African countries test positive in tuberculin tests; (3) molecular pathways involved and the mechanism of development of drug-resistant tuberculosis is far from understood; (3) treating drug-resistant tuberculosis is still a daunting task; (6) tuberculosis is the second-leading cause of death–first being the HIV–due to an infectious disease; (7) in 2010, out of the 88 lakhs patients test positive for TB, 14.5 lakhs patients died; (8) billions of dollars are being spent each year globally for the treatment of tuberculosis; and (9) most of the TB cases are registered in developing countries—that cannot afford high-cost required for the treatment of drug-resistant TB—compared to developed countries, there is an urgent need to find: (i) a way to inhibit drug-resistant tuberculosis; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free-Natural product-based drug that prevents relapse/recurrence of drug-resistant TB.


 From Research Findings to Therapeutic opportunity

This study suggests a natural product-based therapy for life-threatening tuberculosis. Ganoderma lucidum extract, by increasing the expression of its target gene, it may: (1) inhibit TLR-2 expression; (2) increase the expression of phosphatase MKP-1; (3) suppress the expression of Chemokine CXCL5 (C-X-C Motif Chemokine Ligand 5); (4) inhibit the recruitment of polymorphonuclear leukocytes; (5) decrease lung inflammation/injury; (6) promote clearance of M.tuberculosis; and (7) inhibit the progression of pulmonary tuberculosis. Together, pharmacological formulations encompassing “Ganoderma lucidum extract or an active compound isolated from it may be used to treat pulmonary tuberculosis.

ganoderma_lucidum

Figure1. Ganoderma lucidum. Ganoderma lucidum extract inhibits pulmonary tuberculosis via down-regulation of (Toll-like receptor-TLR) TLR-2 and Chemokine CXCL5 and up-regulation of phosphatase MKP-1


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How Ganoderma lucidum:(1) increases the expression of MKP-1; (2) inhibits TLR-2 signaling; and (3) inhibits Chemokine CXCL5 expression

Amount: $300

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Natural product-derived therapy for tuberculosis: Ganoderma lucidum, a medicinal/herbal mushroom, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 29/November/2016, 8.39 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Comments are closed.